VA-INTELSAT
Intelsat, operator of one of the world’s largest integrated satellite and terrestrial networks and leading provider of inflight connectivity (IFC), will deliver years of additional reliable broadband, video distribution and mobile satellite service to customers across three continents thanks to the success of Northrop Grumman’s innovative Mission Extension Vehicle (MEV) that will ultimately provide an expected additional nine years of life to the Intelsat 10-02 (IS-10-02) geosynchronous satellite.
Geosynchronous Earth orbit (GEO) satellites have an average lifespan of about 15-20 years before they start running low on fuel. Intelsat in 2020 became the first satellite operator to commit to deploying two of Northrop Grumman’s MEVs to extend the life of an otherwise healthy satellite. Both MEVs have been successful at their mission and have allowed IS-10-02 and Intelsat 901 (IS-901) to provide five years of service beyond the expected lifespan of the satellite. Under amendments to the original agreements with Northrop Grumman’s SpaceLogistics LLC, both MEVs will stay in space serving Intelsat satellites for several more years, allowing them to operate longer.
- At the end of the current servicing period, MEV-1 will release the IS-901 satellite into the GEO graveyard and then provide service for another Intelsat satellite.
- MEV-2 will remain docked to Intelsat’s current vehicle, IS-10-02, providing life-extension for several years – nearly doubling service from the original contract. The IS-10-02 satellite was manufactured by Airbus Defense & Space, was launched in June 2004 and entered service in August 2004. Capacity on the satellite is shared with Telenor Satellite. Today, MEV-2 is helping to extend the life of IS-10-02, so the satellite can continue providing high-quality media distribution and broadband services to our customers across Europe, the Middle East, Africa and South America. IS-10-02 is a key satellite in the Intelsat-Telenor Satellite video neighborhood, distributing more than 900 channels to nearly 18 million television households across Europe.
“As the largest satellite operator in geosynchronous orbit, Intelsat has always been committed to continuous reliable service, as well as leadership in furthering sustainable space operations,” said Jean-Luc Froeliger, SVP Space Systems at Intelsat. “Intelsat continues to pursue first-of-their-kind innovations to extend the life of its satellites in orbit, while also bringing the industry together to foster information sharing and collaboration across a challenging regulatory environment to achieve sustainable stewardship of the resource of space.”
“This extension is excellent news for our many clients across Europe and the Middle East who are served by THOR 10-02,” said Morten Tengs, CEO of Telenor Satellite. “We pride ourselves on the resilience of our service and, by extending the life of the satellite, we can ensure continuity and hassle-free operations for a number of years.”
MEV Background
In 2020, MEV-1 successfully docked with the IS-901 satellite, a high-performing satellite that was running low on fuel. That marked the first time that two commercial spacecraft docked and began mission-extension service in GEO. The in-space maneuver pointed IS-901 to targeted antennas on Earth and extended its life for another five years of its lifespan.
In 2021, the feat was repeated with a second MEV-2 docking with the IS-10-02 satellite. Unlike the first docking, which was performed in a graveyard orbit a few hundred kilometers above active satellites, this time the MEV-2 docked with IS-10-02 in its original orbital slot and avoided any interruption of services to customers, resulting in the first-ever in-orbit servicing of a live commercial satellite in GEO.
About Intelsat
Intelsat’s global team of professionals is focused on providing seamless and secure, satellite-based communications to government, NGO and commercial customers through the company’s next-generation worldwide network and managed services. Bridging the digital divide by operating one of the world’s largest and most advanced satellite fleet and connectivity infrastructures, Intelsat enables people and their tools to speak over oceans, see across continents and listen through the skies to communicate, cooperate and coexist. Since its founding six decades ago, the company has been synonymous with satellite-industry “firsts” in service to its customers and the planet. Leaning on a legacy of innovation and focusing on addressing a new generation of challenges Intelsat team members now have their sights on the “next firsts” in space as they disrupt the field and lead in the digital transformation of the industry.
Follow Us on Social Media:
X | LinkedIn | Instagram | YouTube
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240523619448/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
